Article Text

Download PDFPDF
CASE REPORT
Brown-Vialetto-Van Laere syndrome: a novel diagnosis to a common presentation
  1. Qalab Abbas,
  2. Sidra Kaleem Jafri,
  3. Sidra Ishaque,
  4. Arshalooz Jamila Rahman
  1. Department of Pediatrics and Child Health, Aga Khan University Hospital, Karachi, Pakistan
  1. Correspondence to Dr Qalab Abbas, qalababbas{at}gmail.com

Summary

Brown-Vialetto-Van Laere syndrome (BVVLS) or riboflavin transporter deficiency (OMIM 211530) is a rare treatable autosomal recessive neurodegenerative disorder. This condition is associated with progressive pontobulbar palsy. We describe the clinical course of a 16-month-old boy with BVVLS and a novel homozygous mutation from Pakistan. Our patient presented with stridor and respiratory insufficiency. Hearing loss which is the most common sign of this condition was absent, making it an unusual presentation of BVVLS. His examination revealed ptosis and tongue fasciculation. His riboflavin receptor mutational analysis showed the homozygous mutation in the SLC52A3 gene. Per oral riboflavin was administered, and subsequently, he was able to be weaned off the ventilator. Now the child is improving and attaining developmental milestones.

  • neuromuscular disease
  • mechanical ventilation

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors QA was involved in managing the patient, doing the literature search and writing, editing and final proofreading the manuscript. SKJ and SI were involved in doing the literature search and writing, editing and final proofreading the manuscript. AJR was involved in managing the patient and reviewing and proofreading the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Parental/guardian consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.